The enrichment of BTBD19 in M2-associated pathways implies that it may drive macrophage polarization toward an immunosuppressive phenotype, establishing a microenvironment conducive to tumor progression and resistance to immunotherapeutic interventions. This evidence concerns the gene BTBD19 and neoplasm.